Copyright: ©Author(s) 2026.
World J Gastroenterol. Dec 21, 2026; 32(47): 122668
Published online Dec 21, 2026. doi: 10.3748/wjg.122668
Published online Dec 21, 2026. doi: 10.3748/wjg.122668
Figure 4 ZFP36 interacts with gastric carcinoma-related mRNAs in AGS cells.
A: Western blot validation of ZFP36 immunoprecipitation using an anti-Flag monoclonal antibody; B: Pie chart depicting peak distribution across the genome for two biological replicates of ZFP36-bound fragments; C: Consensus motifs enriched among ZFP36-bound peaks (top five) from two replicate trials are displayed; D: Spatial distribution of UCGC-enriched sequences as determined by Ablife analysis across both experimental replicates; E: ZFP36 binding peak within the RPS25 gene are presented. Left: Read density landscape of ZFP36-binding peaks across RPS25. Right: Reverse transcription-quantitative polymerase chain reaction quantification of RPS25 expression from improved RNA immunoprecipitation sequencing data. aP < 0.05.
- Citation: Yu PJ, Zhu SM, Cai BJ, Ma XM, Qiao WJ, Han JJ, Zhang CW. Zfp36 zinc finger CCCH-type inhibits gastric cancer progression by upregulating lipase G and binding its 3’ untranslated region. World J Gastroenterol 2026; 32(47): 122668
- URL: https://www.wjgnet.com/1007-9327/full/v32/i47/122668.htm
- DOI: https://dx.doi.org/10.3748/wjg.122668